Ten kHz spinal cord stimulation for the treatment of chronic peripheral polyneuropathy: 12-Month results from prospective open-label pilot study

被引:8
作者
Galan, Vincent [1 ]
Scowcroft, James [2 ]
Chang, Paul [1 ]
Li, Sean [3 ]
Staats, Peter [3 ]
Subbaroyan, Jeyakumar [4 ]
Caraway, David [4 ]
机构
[1] Georgia Pain Care, 1365 Rock Quarry Rd,Suite 202, Stockbridge, GA 30281 USA
[2] KC Pain Ctr, Lees Summit, MO USA
[3] Premier Pain Ctr, Shrewsbury, NJ USA
[4] Nevro Corp, Redwood City, CA USA
关键词
10 kHz SCS; chronic peripheral polyneuropathy; visual analog scale; QUALITY-OF-LIFE; 10-KHZ HIGH-FREQUENCY; CHRONIC PAIN; CHRONIC BACK; NEUROPATHY; OUTCOMES; EFFICACY; LIMB; SCS; MULTICENTER;
D O I
10.1111/papr.13059
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background The goal of this study was to demonstrate that the paresthesia-independent 10 kHz spinal cord stimulation (SCS) can provide long-term pain relief in patients with peripheral polyneuropathy (PPN). Clinically diagnosed subjects with PPN refractory to conventional medical management were enrolled in this prospective, multicenter study between November 2015 and August 2016, after institutional review board approval and patient informed consent were obtained. Methods Subjects underwent trial stimulation utilizing 2 epidural leads, and if successful, were implanted with a permanent 10 kHz SCS system and followed up for 12 months post-implant. Outcome measures included adverse events, pain, neurological assessments, disability, function, quality of life, pain interference, sleep, satisfaction, and global impression of change. Data are presented as descriptive statistics. Permanent implant population results are reported as mean +/- standard error. Results Twenty-one of the 26 trialed subjects had a successful trial and 18 received a permanent implant. All subjects had the leads placed anatomically without the need for paresthesia. Subjects experienced significant and sustained pain relief (at least 65% at all timepoints) whereas physicians noted improvements in neurological function. Significant improvements in disability, function, sleep, sensory, and affective dimensions of pain were reported at all timepoints. All adverse events were resolved without sequelae. Conclusion Findings from this study suggest that 10 kHz SCS may provide sustained pain relief and disability improvements in patients suffering from PPN.
引用
收藏
页码:898 / 906
页数:9
相关论文
共 47 条
  • [31] Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain: 12-month results from the COMFORT-randomized controlled trial
    Hatheway, John
    Hersel, Alexander
    Engle, Mitchell
    Gutierrez, Genaro
    Khemlani, Vishal
    Kapural, Leonardo
    Moore, Gregory
    Ajakwe, Reginald
    Trainor, Drew
    Hah, Jennifer
    Staats, Peter S.
    Makous, James
    Heit, Gary
    Kottalgi, Shilpa
    Desai, Mehul J.
    REGIONAL ANESTHESIA AND PAIN MEDICINE, 2024,
  • [32] Long-Term Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines: Results From a 36-Month, Multicenter, Open-Label Extension Study
    Schlessinger, Joel
    Dover, Jeffrey S.
    Joseph, John
    Monheit, Gary
    Nelson, Diane B.
    Albright, Craig D.
    Axford-Gatley, Robert A.
    Cohen, Joel L.
    DERMATOLOGIC SURGERY, 2014, 40 (02) : 176 - 183
  • [33] Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study
    Karp, Jordan F.
    Weiner, Debra K.
    Dew, Mary A.
    Begley, Amy
    Miller, Mark D.
    Reynolds, Charles F., III
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 25 (06) : 633 - 642
  • [34] Armodafinil for the Treatment of Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury: A 12-Week, Randomized, Double-Blind Study followed by a 12-Month Open-Label Extension
    Menn, Stuart J.
    Yang, Ronghua
    Lankford, Alan
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2014, 10 (11): : 1181 - 1191
  • [35] Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study
    Ticau, Simina
    Aldinc, Emre
    Polydefkis, Michael
    Adams, David
    Coelho, Teresa
    Ueda, Mitsuharu
    Hale, Cecilia
    Vest, John
    Nioi, Paul
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 (01): : 1 - 11
  • [36] Burst spinal cord stimulation can attenuate pain and its affective components in chronic pain patients with high psychological distress: results from the prospective, international TRIUMPH study
    Hagedorn, Jonathan M.
    Falowski, Steven M.
    Blomme, Bram
    Capobianco, Robyn A.
    Yue, James J.
    SPINE JOURNAL, 2022, 22 (03) : 379 - 388
  • [37] Comparison of 10-kHz High-Frequency and Traditional Low-Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-Month Results From a Multicenter, Randomized, Controlled Pivotal Trial
    Kapural, Leonardo
    Yu, Cong
    Doust, Matthew W.
    Gliner, Bradford E.
    Vallejo, Ricardo
    Sitzman, B. Todd
    Amirdelfan, Kasra
    Morgan, Donna M.
    Yearwood, Thomas L.
    Bundschu, Richard
    Yang, Thomas
    Benyamin, Ramsin
    Burgher, Abram H.
    NEUROSURGERY, 2016, 79 (05) : 667 - 676
  • [38] Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations
    Ueberall, Michael A.
    Mueller-Schwefe, Gerhard H. H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (07) : 1413 - 1429
  • [39] SAFETY, TOLERABILITY, AND EFFICACY OF REPEAT-DOSE INJECTIONS OF INCOBOTULINUMTOXINA IN THE TREATMENT OF UPPER FACIAL LINES: RESULTS FROM A PROSPECTIVE, OPEN-LABEL, PHASE 3 STUDY
    Kerscher, Martina
    Connolly, Simon A.
    Biwer, Bernard
    Weissenberger, Petra
    Kestemont, Philippe
    Noah, Ernst M.
    Sattler, Gerhard
    Trevidic, Patrick
    TOXICON, 2018, 156 : S60 - S60
  • [40] Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study
    Fischer, Tanja
    Sattler, Gerhard
    Prager, Welf
    Rzany, Berthold
    Pavicic, Tatjana
    Gauglitz, Gerd
    Weissenberger, Petra
    Riaz, Shahbaz
    Kerscher, Martina
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (05) : 461 - 469